Influence of unrecognized molecular heterogeneity on randomized clinical trials

Rebecca Betensky, David N. Louis, J. Gregory Cairncross

Research output: Contribution to journalArticle

Abstract

Purpose: In solid tumor oncology, decisions regarding treatment and eligibility for trials are governed by histologic diagnosis. Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes. Patients and Methods: To illustrate how unrecognized molecular heterogeneity might obscure a truly effective new therapy for cancer, we analyzed the planning assumptions and results of a hypothetical randomized controlled trial of chemoradiotherapy for a cancer found to be drug sensitive in preliminary phase II studies. Results: Randomized controlled trials of effective cancer therapies can be falsely negative if therapeutic benefit is overestimated during study design because of enrichment of phase II trials for treatment-sensitive subtypes, a beneficial effect in responding patients is diluted by large numbers of nonresponding patients, or a beneficial effect in responders is reversed by a negative effect in nonresponders. Conclusion: Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer

Original languageEnglish (US)
Pages (from-to)2495-2499
Number of pages5
JournalJournal of Clinical Oncology
Volume20
Issue number10
DOIs
StatePublished - May 15 2002

Fingerprint

Randomized Controlled Trials
Neoplasms
Histology
Therapeutics
Chemoradiotherapy
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Influence of unrecognized molecular heterogeneity on randomized clinical trials. / Betensky, Rebecca; Louis, David N.; Cairncross, J. Gregory.

In: Journal of Clinical Oncology, Vol. 20, No. 10, 15.05.2002, p. 2495-2499.

Research output: Contribution to journalArticle

Betensky, Rebecca ; Louis, David N. ; Cairncross, J. Gregory. / Influence of unrecognized molecular heterogeneity on randomized clinical trials. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 10. pp. 2495-2499.
@article{3b0095072c214a2bbebfac203d821074,
title = "Influence of unrecognized molecular heterogeneity on randomized clinical trials",
abstract = "Purpose: In solid tumor oncology, decisions regarding treatment and eligibility for trials are governed by histologic diagnosis. Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes. Patients and Methods: To illustrate how unrecognized molecular heterogeneity might obscure a truly effective new therapy for cancer, we analyzed the planning assumptions and results of a hypothetical randomized controlled trial of chemoradiotherapy for a cancer found to be drug sensitive in preliminary phase II studies. Results: Randomized controlled trials of effective cancer therapies can be falsely negative if therapeutic benefit is overestimated during study design because of enrichment of phase II trials for treatment-sensitive subtypes, a beneficial effect in responding patients is diluted by large numbers of nonresponding patients, or a beneficial effect in responders is reversed by a negative effect in nonresponders. Conclusion: Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer",
author = "Rebecca Betensky and Louis, {David N.} and Cairncross, {J. Gregory}",
year = "2002",
month = "5",
day = "15",
doi = "10.1200/JCO.2002.06.140",
language = "English (US)",
volume = "20",
pages = "2495--2499",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Influence of unrecognized molecular heterogeneity on randomized clinical trials

AU - Betensky, Rebecca

AU - Louis, David N.

AU - Cairncross, J. Gregory

PY - 2002/5/15

Y1 - 2002/5/15

N2 - Purpose: In solid tumor oncology, decisions regarding treatment and eligibility for trials are governed by histologic diagnosis. Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes. Patients and Methods: To illustrate how unrecognized molecular heterogeneity might obscure a truly effective new therapy for cancer, we analyzed the planning assumptions and results of a hypothetical randomized controlled trial of chemoradiotherapy for a cancer found to be drug sensitive in preliminary phase II studies. Results: Randomized controlled trials of effective cancer therapies can be falsely negative if therapeutic benefit is overestimated during study design because of enrichment of phase II trials for treatment-sensitive subtypes, a beneficial effect in responding patients is diluted by large numbers of nonresponding patients, or a beneficial effect in responders is reversed by a negative effect in nonresponders. Conclusion: Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer

AB - Purpose: In solid tumor oncology, decisions regarding treatment and eligibility for trials are governed by histologic diagnosis. Despite this reliance on histology and the assumption that histology defines the disease, underlying molecular heterogeneity likely differentiates among patients' outcomes. Patients and Methods: To illustrate how unrecognized molecular heterogeneity might obscure a truly effective new therapy for cancer, we analyzed the planning assumptions and results of a hypothetical randomized controlled trial of chemoradiotherapy for a cancer found to be drug sensitive in preliminary phase II studies. Results: Randomized controlled trials of effective cancer therapies can be falsely negative if therapeutic benefit is overestimated during study design because of enrichment of phase II trials for treatment-sensitive subtypes, a beneficial effect in responding patients is diluted by large numbers of nonresponding patients, or a beneficial effect in responders is reversed by a negative effect in nonresponders. Conclusion: Molecular heterogeneity, if it confers different risks to patients and is unaccounted for in the design of a randomized study, can result in a clinical trial that is underpowered and fails to detect a truly effective new therapy for cancer

UR - http://www.scopus.com/inward/record.url?scp=0037093249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037093249&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.06.140

DO - 10.1200/JCO.2002.06.140

M3 - Article

VL - 20

SP - 2495

EP - 2499

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -